Solna, April 23rd 2018 - Today the Nordic affiliates of Janssen and Galderma announced their long-term partnership for the marketing of TREMFYA® (guselkumab) for the treatment of moderate to severe plaque psoriasis.

“Both Janssen and Galderma bring with them a rich heritage in dermatology. Combining our expertise will strengthen our presence and reach across the Nordics and help fulfill our common goal; to provide the individual psoriasis patient with the best possible treatment option”, says Tim Schenk, Commercial Director Nordic, Janssen.

Peter Worsoe, managing director at Galderma Nordic, is also excited about introducing TREMFYA® to the market together with Janssen; “This agreement will broaden our dermatology portfolio in the Nordic countries, offering treatments ranging from mild to severe dermatological conditions.”

The aim of the collaboration is to more comprehensively support patients and health care practitioners (HCP) with the new biologic therapy option as well as to offer updates on the latest progress in the treatment of patients with plaque psoriasis.

TREMFYA® is available in Denmark, Norway, Sweden and Finland for treatment of patients with moderate to severe plaque psoriasis. For more information on TREMFYA® visit www.janssen.com. For questions regarding the collaboration between Janssen-Cilag Nordics and Galderma Nordic AB, please contact us according to above details.

About Janssen

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Janssen-Cilag AB is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

About Galderma

Galderma, Nestlé Skin Health’s medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically defined and medically proven solutions for the skin, hair and nails.